Lupus study aims to unlock secrets of immune system attacks
NCT ID NCT00582881
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at how the immune system behaves in people with lupus (SLE) and mixed connective tissue disease (MCTD). Researchers measured immune cell responses and tracked disease activity over time. The goal was to better understand these long-term autoimmune diseases, which often affect young women, especially Black and Hispanic women. No treatment was given; this was an observation-only study to gather information for future therapies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
124 people
The number who actually took part.
- Started
-
Oct 2007
- Finished
-
Jun 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), mixed connective tissue disease (MCTD) or undifferentiated connective tissue disease (UCTD)
- Ages
-
18 to 100 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients with known rheumatic diseases including systemic lupus erythematosus, rheumatoid arthritis, connective tissue disease, undifferentiated connective tissue disease Exclusion Criteria: * Poor venous access, unstable medical problems or significant cardiopulmonary disease, anemia, leukopenia, thrombocytopenia, anticoagulation therapy, recent significant changes in medication or pregnacy. Patient cannot be taking large dose of corticosteroids (above 30mg per day) or cytotoxic drugs (cyclophosphamide, azathiprine, cyclosporine, methotrexate).
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Mixed connective tissue disease (MCTD) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Miami Miller School of Medicine
Miami, Florida, 33136, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Bispecific antibody aims to wipe out Lupus-Causing immune cells
- Can a single cell therapy calm multiple autoimmune diseases?
- Can a Three-Drug combo quiet lupus kidney flares?
- Can a new antibody tame lupus flares?
- Can a single infusion of reprogrammed immune cells quiet lupus kidney disease?
- Eye tests could spot silent vision damage in lupus patients